255 related articles for article (PubMed ID: 26290435)
21. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
Merrill JT; Wallace DJ; Wax S; Kao A; Fraser PA; Chang P; Isenberg D;
Arthritis Rheumatol; 2018 Feb; 70(2):266-276. PubMed ID: 29073347
[TBL] [Abstract][Full Text] [Related]
23. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
Emu B; Luca D; Offutt C; Grogan JL; Rojkovich B; Williams MB; Tang MT; Xiao J; Lee JH; Davis JC
Arthritis Res Ther; 2012 Jan; 14(1):R6. PubMed ID: 22225620
[TBL] [Abstract][Full Text] [Related]
24. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
25. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
26. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
Nakayama Y; Kosek J; Capone L; Hur EM; Schafer PH; Ringheim GE
J Immunol; 2017 Oct; 199(7):2388-2407. PubMed ID: 28848067
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
28. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Jacobi AM; Huang W; Wang T; Freimuth W; Sanz I; Furie R; Mackay M; Aranow C; Diamond B; Davidson A
Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
[TBL] [Abstract][Full Text] [Related]
29. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials.
Wagner FD; Schreiber S; Bagger Y; Bruzelius K; Falahati A; Sternebring O; Ravi A; Pinton P
Clin Transl Sci; 2024 May; 17(5):e13832. PubMed ID: 38769747
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
Munafo A; Priestley A; Nestorov I; Visich J; Rogge M
Eur J Clin Pharmacol; 2007 Jul; 63(7):647-56. PubMed ID: 17473917
[TBL] [Abstract][Full Text] [Related]
32. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
35. B cell alterations during BAFF inhibition with belimumab in SLE.
Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
[TBL] [Abstract][Full Text] [Related]
36. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
37. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
Minocha M; Zeng J; Medema JK; Othman AA
Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
[TBL] [Abstract][Full Text] [Related]
39. Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy.
Golmia AP; Martin R; Hislop C; Scheinberg M
Rheumatology (Oxford); 2014 May; 53(5):957-8. PubMed ID: 24226636
[No Abstract] [Full Text] [Related]
40. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
